테라반스 바이오파마(TBPH) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

TBPH

Theravance Biopharma Inc

7월 27일 4:00 PM ET (한국 7/28 05:00)

$16.86

+0.00 +0.00%

🌙 7월 27일 4:10 PM ET (한국 7/28 05:10)

$16.86

+0.00 +0.00%

테라반스 바이오파마(TBPH) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$874M

스몰캡

P/E

7.7

저평가 구간

배당수익률

없음

52주 위치

59%

저점 +56% · 고점 -20%

애널리스트

보유

B-

Fundamental health

vs. Biotechnology 소형주

수익성

Top 6%

성장

Top 57%

밸류에이션

Top 62%

재무 안정

Top 33%

💰 Is this stock pricier than usual right now?

Compared to this company's own recent 2년 (not other companies).

Very cheap

Cheap

Typical

Pricey

Very pricey

Simply put — what you pay today to own $1 of this company's yearly earnings is 8원. Over the past 2년, it usually traded around 7원. On the pricier side versus its own history.

Pricy doesn't mean bad — it means expectations are already baked in.· based on 2.1 profitable years

Index ⓘ	RUT	P/E ⓘ	7.65	EPS (ttm) ⓘ	2.2	Insider Own ⓘ	6.46%	Shs Outstand ⓘ	51.5M	Perf Week ⓘ	0.3%
Market Cap ⓘ	0.87B	Forward P/E ⓘ	9.04	EPS next Y ⓘ	-29.79%	Insider Trans ⓘ	-10.22%	Shs Float ⓘ	48.5M	Perf Month ⓘ	-3.05%
Enterprise Value ⓘ	0.55B	PEG ⓘ	-	EPS next Q ⓘ	0.07	Inst Own ⓘ	95.98%	Short Float ⓘ	8.88%	Perf Quarter ⓘ	2.43%
Income ⓘ	0.11B	P/S ⓘ	7.96	EPS this Y ⓘ	28.91%	Inst Trans ⓘ	-1.08%	Short Ratio ⓘ	7.37	Perf Half Y ⓘ	-16.7%
Sales ⓘ	0.11B	P/B ⓘ	2.99	EPS next 5Y ⓘ	-11.87%	ROA ⓘ	28.08%	Short Interest ⓘ	4.31M	Perf YTD ⓘ	-9.89%
Book/sh ⓘ	5.64	P/C ⓘ	2.21	EPS past 3/5Y ⓘ	-	ROE ⓘ	50.17%	52W High ⓘ	-19.83% ($21.03)	Perf Year ⓘ	52.86%
Cash/sh ⓘ	7.61	P/FCF ⓘ	3.25	Sales past 3/5Y ⓘ	27.91% 8.38%	ROIC ⓘ	32.43%	52W Low ⓘ	55.79% ($10.82)	Perf 3Y ⓘ	75.26%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	95.41	EPS Y/Y TTM ⓘ	291.2%	Gross Margin ⓘ	94.81%	Volatility(W/M) ⓘ	0.51% 0.88%	Perf 5Y ⓘ	23.34%
Dividend TTM ⓘ	-	EV/Sales ⓘ	5.03	Sales Y/Y TTM ⓘ	68.2%	Oper. Margin ⓘ	0.08%	ATR (14) ⓘ	0.18	Perf 10Y ⓘ	-30.01%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	13.14	EPS Q/Q ⓘ	64.79%	Profit Margin ⓘ	104.34%	RSI (14) ⓘ	50.58	Recom ⓘ	3
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	13.14	Sales Q/Q ⓘ	15.02%	SMA20 ⓘ	-0.41% ($16.93)	Beta ⓘ	0.19	Target Price ⓘ	$17.67
Payout ⓘ	-	Debt/Eq ⓘ	0.25	Earnings ⓘ	2026/5/7	SMA50 ⓘ	1.26% ($16.65)	Rel Volume ⓘ	0.68	Prev Close ⓘ	$16.86
Employees ⓘ	90	LT Debt/Eq ⓘ	0.22	EPS/Sales Surpr. ⓘ	-457.14% -0.47%	SMA200 ⓘ	-0.82% ($17)	Avg Volume(3M) ⓘ	0.58M	Price ⓘ	$16.86
IPO ⓘ	2014/5/16	Option/Short ⓘ	Yes/Yes			Trades ⓘ	3930	Volume ⓘ	395,416	Change ⓘ	-

Quarterly earnings trend SEC filings · USD

24.6

24.9

24.12

25.3

25.6

25.9

25.12

26.3

Revenue Net income 최근 분기: 매출 $18M (YoY +15%) · 순이익 $-5M (YoY +64%)

📊 Theravance Biopharma Inc (TBPH) Investment Analysis

What kind of company is Theravance Biopharma Inc?

테라반스 바이오파마(TBPH) 방어주

Healthcare · Biotechnology

Healthcare Stocks

Theravance Biopharma is a biotech company built around respiratory therapeutic assets. It shares the U.S. commercialization revenue from its lead asset, YUPELRI (revefenacin) inhalation solution, with its partner, while also collecting revenue from royalties on partner assets such as the legacy TRELEGY royalty. The ticker is TBPH. Recently, the company has significantly scaled back its in-house drug development and restructured its business around a royalty and revenue collection model.

Learn more about Theravance Biopharma Inc →

Market Cap

$0.9B

Approx. KRW 1.2 trillion

⚖️ 0% of Samsung Electronics

Market Cap Rank2753

Employees90people

IPO2014/05/16

Current Price$16.86 ≈ 23,098원

📌 RUT · NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 7일 (목) · 장 시작 전 EPS -457.1% 매출 -0.5%

🔔 Earnings release 2026년 3월 19일 (목) · 장 시작 전 EPS +5.3% 매출 -18.9%

Is it profitable?

Solid company — profitability & finances both healthy

Strong earnings and excellent financial health

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

0.1%

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology 소형주 Median -210.9% · Top 15%

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

104.3%

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology 소형주 Median -187.6% · Top tier

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

94.8%

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology 소형주 Median 84.9% · Top 21%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

50.2%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 소형주 Median -37.5% · Top tier

💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)

ROA

Annual earnings relative to total company assets

28.1%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 소형주 Median -21.8% · Top tier

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

32.4%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 소형주 Median -25.0% · Top tier

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.25

✓ Healthy debt

My positionMid-range

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

13.14

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

13.14

✓ 우수

My positionTop 25%

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$17.67

현재가 대비 +4.8%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

9.04배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

내년 EPS 예상 성장률

-29.8%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

-11.9%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

High Earnings Volatility

Frequently misses analyst estimates

예상 상회

예상 부합

예상 하회

상회 비율

-84.0%

평균 서프라이즈

2026.05.07

하회

실적 $0.01 · 예상 $0.09 -86.1%

2026.03.19

하회

실적 $0.06 · 예상 $0.33 -81.9%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth

Mid-range within the industry

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+28.9%

우수

My positionTop 25%

Low range Average High range

방어주 소형주 Median 4.7% · Top 25%

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

-29.8%

부진

My positionBottom 25%

Low range Average High range

방어주 소형주 Median 10.1% · Bottom 11%

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

-11.9%

부진

My positionBottom 25%

Low range Average High range

방어주 소형주 Median 3.4% · Bottom 10%

📊 How much has it grown? (actual results)

Past 5-Year Revenue

How much revenue grew over the past 5 years

+8.4%

양호

My positionMid-range

Low range Average High range

방어주 소형주 Median 6.7% · Top 45%

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+15.0%

양호

My positionMid-range

Low range Average High range

방어주 소형주 Median 4.9% · Top 36%

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -45%p below the market

TBPH +23.3% · S&P 500 +68.3%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-45.0%p

Significantly behind the market

vs Health Care (XLV)

-1.2%p

roughly in line with the sector average

1-year basis

vs S&P 500

+36.8%p

well ahead of the market

vs Health Care (XLV)

+33.1%p

well ahead of the sector average

Rank among peers

5-year return Top 18% Based on 123 peers

1-year return Upper-Mid (48%) Based on 154 peers

Current position within 52-week range

Low (-55.8%p) High (-19.8%p)

Current price is 55.8% above the 52-week low and 19.8% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-33.7%

Annualized volatility

51.6%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟡

Current diagnosis · 2026-07-27

Squeeze — volatility contraction, breakout imminent

Band width narrowed to 1.6%. Big move may be near. Inside the Ichimoku cloud (neutral).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-07-27

Neutral zone — weak trend

MACD 0.030 · Signal 0.063 · Hist -0.033. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢

Current diagnosis · 2026-07-27

Bullish zone

RSI 50.5 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 17.1.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry

Cheap on Vs. Earnings·Vs. Assets·Vs. Sales, In line with peers on Vs. Cash Flow

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Cheap

🏢 Vs. Assets Cheap

🧾 Vs. Sales Cheap

💧 Vs. Cash Flow Mid-range

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

7.65x

✓ Cheap

My positionMid-range

Low range Average High range

Biotechnology 소형주 median 7.65x · Around the industry average

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

9.04x

✓ Very cheap

My positionTop 25%

Low range Average High range

Biotechnology 소형주 median 18.33x · Top 16% — relatively cheap within the industry

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

2.99x

✓ Cheap

My positionMid-range

Low range Average High range

Biotechnology 소형주 median 3.34x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

7.96x

✓ Cheap

My positionMid-range

Low range Average High range

Biotechnology 소형주 median 14.61x · Around the industry average

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

95.41x

✓ Pricey

My positionBottom 25%

Low range Average High range

Biotechnology 소형주 median 19.26x · Bottom 11% — expensive within the industry

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

3.25x

✓ Very cheap

My positionTop 5%

Low range Average High range

Biotechnology 소형주 median 14.14x · Top 1% — relatively cheap within the industry

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$17.67 vs. current price +4.8%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology 소형주

Who owns it?

Ownership backdrop is unfavorable

Insider net selling -10.2% · Institutional net selling -1.1% · Short interest moderate 8.9% · Short interest fell -1.2%p over the last 90 days

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-10.2%

Insiders large net selling

🏦 Institutions (funds & investors)

-1.1%

Institutions net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 96.0%

Institution-led, stable structure

Healthcare 소형주 Median 65.6%

🧑‍💼 Insiders 6.5%

Meaningful insider stake

Healthcare 소형주 Median 17.6%

👤 Retail investors (estimated) 0.0%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

8.9%

Moderate

Healthcare 소형주 Median 11.2%

Past 90 days 📉 -1.2%p decrease

Short interest days to cover

7.4 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 51.5M주

Float (tradable shares) 48.5M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding TBPH

ETFs with the highest weightings · 10 total shown

PBE

Invesco Biotechnology & Genome ETF

State Street SPDR S&P Pharmaceuticals ETF

1.42%

$475M

PILL

Direxion Daily Pharmaceutical & Medical Bull 3X ETF

1.02%

$21M

FDLS

Inspire Fidelis Multi Factor ETF

0.90%

$228M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
TBPH This Stock	$873.8M	7.7 ▲	3.0 ▼	50.17% ▲	-	+0.0%
LLY	$1.13T	43.1 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.1%
JNJ	$640.9B	30.8 ▼	7.5 ▼	25.74% ▲	2.02% ▲	+1.0%
ABBV	$453.9B	126.7 ▼	-	15221.82% ▲	2.67% ▲	-0.9%
UNH	$379.3B	26.9 ▼	3.9 ▼	12.49% ▲	2.16% ▲	-0.7%
MRK	$323.0B	36.8 ▼	7.0 ▼	18.97% ▲	2.5% ▲	-0.2%
Sector Avg	-	26.1	2.7	-48.83%	1.23%	-

FAQ

What kind of company is 테라반스 바이오파마(TBPH)?

테라반스 바이오파마(TBPH) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of TBPH?

The market cap of TBPH is approximately $874M, ranking 2,753 within its sector.

What is the P/E ratio of TBPH?

TBPH has a P/E ratio of approximately 7.7x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for TBPH?

TBPH has recorded a 52-week high of $21.03 and a low of $10.82.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.